Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03973918 · ClinicalTrials.gov registry record · Phase 2
Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT03973918 is a Phase 2 study that was terminated before completion, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 5 participants.
The verdict
NCT03973918, a Phase 2 study, was terminated before completion, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
The goal of this study is to estimate the efficacy of encorafenib and binimetinib as measured by radiographic response in recurrent high-grade primary brain tumors.
Interventions
- DRUG Binimetinib
- DRUG Encorafenib
- BIOLOGICAL Research Bloods
- BIOLOGICAL Tumor Tissue
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2019-07-29 |
| Est. Completion | 2023-10-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03973918
The ClinicalTrials.gov registry entry for NCT03973918 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Binimetinib is the first listed.
NCT03973918 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03973918 about?
NCT03973918 is a clinical study titled "Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG". The goal of this study is to estimate the efficacy of encorafenib and binimetinib as measured by radiographic response in recurrent high-grade primary brain tumors.
What is the current status of trial NCT03973918?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2019-07-29. Estimated completion is 2023-10-01.
What interventions are being tested in trial NCT03973918?
The interventions under investigation include: Binimetinib (DRUG), Encorafenib (DRUG), Research Bloods (BIOLOGICAL), Tumor Tissue (BIOLOGICAL).
Who is sponsoring clinical trial NCT03973918?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.